Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. 2000. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 284(15):1954–1961.
Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM. 2000. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 343(22):1603–1607.
Mandel JS, Church TR, Ederer F, Bond JH. 1999. Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 91(5):434–437.
Taplin SH, Barlow W, Urban N. 1995a. Erratum: Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 87(8):610.
Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, Nefcy P. 1995b. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 87(6):417–426.
The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Appendix D Overview of Harvard Model--Karen M. Kuntz, ScD. ."
Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary . Washington, DC: The National Academies Press,
Please select a format: